Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 464-466

  Numakura, Kazuyuki ^a   Tsuchiya, Norihiko ^a   Akihama, Susumu ^a   Inoue, Takamitsu ^a   Narita, Shintaro ^a   Huang, Mingguo ^a   Satoh, Shigeru ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Mammalian target of rapamycin inhibitor; Sarcomatoid renal cell carcinoma

Indexed keywords

DOXORUBICIN; GEMCITABINE; TEMSIROLIMUS;

ADULT; ARTICLE; BONE METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; KIDNEY TUMOR; LOW BACK PAIN; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SARCOMATOID CARCINOMA;

EID: 84901201057     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2118     Document Type: Article

References (12)

1. Sun M, Thuret R, Abdollah F, et al: Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59:135-141, 2011.
2. Basso M, Cassano A and Barone C: A survey of therapy for advanced renal cell carcinoma. Urol Oncol 24:121-133, 2010.
3. de Peralta-Venturina M, Moch H, Amin M, et al: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25: 275-284, 2001.
4. Haas NB, Lin X, Manola J, et al: A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29: 761-767, 2012.
5. Molina AM, Tickoo SK, Ishill N, et al: Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 34: 454-459, 2011.
6. Tannir NM, Plimack E, Ng C, et al: A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62: 1013-1019, 2012.
7. Nanus DM, Garino A, Milowsky MI, et al: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101: 1545-1551, 2004.
8. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
9. Areses MC, Herranz UA, Ferrán BB, et al: Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Med Oncol 29: 795-798, 2012.
10. Staehler M, Haseke N, Roosen A, et al: Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 15: 287-291, 2010.
11. Michaelson DF, McDermott MB, Atkins DC, et al: Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. J Clin Oncol 28 (suppl 15): e15076, 2010.
12. Corradetti MN and Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25: 6347-6360, 2006.